Author + information
- Received December 13, 1982
- Accepted December 15, 1982
- Published online June 1, 1983.
- John S. Schroeder, MD, FACC*,
- Irene H. Lamb, RN,
- Michael R. Bristow, MD, PhD,
- Robert Ginsburg, MD,
- Joseph Hung, MD and
- Bruce J. McAuley, MD
- ↵*Address for reprints: John S. Schroeder, MD, Cardiology Division, Stanford University Medical Center, Stanford, California 94305.
In 43 patients with variant angina, the cardiovascular event rate during diltiazem therapy was compared with that in an equal time period before initiation of therapy. Cardiovascular events, that is, myocardial infarction, sudden death and hospitalization for prolonged angina, were decreased significantly (p < 0.01) during the initial 6 months and mean 19.6 months of therapy. Based on the binomial principie, there were 22 events during the mean 19.6 months before therapy and 2 events during the equal time period on therapy. No patient died during follow-up. The frequency of angina was decreased by 94%. Diltiazem was well tolerated by all patients and no patient had to discontinue therapy because of adverse effects. It is concluded that long-term diltiazem therapy reduces cardiovascular events in patients with variant angina.
- Received December 13, 1982.
- Accepted December 15, 1982.
- American College of Cardiology Foundation